Keywords: b-ms, abatacept, inhibits, ra, damage, drugmaker, bristol-myers
B-MS' Abatacept inhibits RA damage
Article | 20 June 2005
US drugmaker Bristol-Myers Squibb's investigational drug abatacept inhibits the progression of joint damage in subjects with active rheumatoid arthritis, independent ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
